May 9 |
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 8 |
Argenx SE Q1 2024 Earnings Preview
|
May 7 |
argenx announces results of Annual General Meeting of Shareholders
|
May 7 |
argenx: Innovation Over Losses In Autoimmune Arena
|
May 7 |
argenx to Present at BofA Securities 2024 Health Care Conference
|
May 2 |
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
|
Apr 16 |
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
|
Apr 10 |
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
|